Ledipasvir/Sofosbuvir plus /-Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

被引：0
作者：
Curry, Michael P. [1 ]
Bacon, Bruce [2 ]
Dieterich, Douglas T. [3 ]
Guest, Lauren [4 ]
Kowdley, Kris [5 ]
Lee, Yoori [4 ]
Tsai, Naoky [6 ]
Younossi, Zobair [7 ]
Flamm, Steven L. [8 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Med, Boston, MA 02215 USA
[2] St Louis Univ, Sch Med, Med, St Louis, MO USA
[3] Icahn Sch Med Mt Sinai, Med, New York, NY 10029 USA
[4] Trio Hlth Analyt, La Jolla, CA USA
[5] Swedish Med Ctr, Med, Seattle, WA USA
[6] Univ Hawaii, Queens Med Ctr, Med, Honolulu, HI 96822 USA
[7] Inova Fairfax Hosp, Med, Falls Church, VA USA
[8] Northwestern Univ, Feinberg Sch Med, Med, Chicago, IL 60611 USA
来源：
TRANSPLANTATION | 2016年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
O-36
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 50 条
  • [21] Real-world HCV treatment in HCV-HIV coinfected population: Data from the TRIO network
    Jayaweera, Dushyantha
    Radtchenko, Janna
    Althoff, Keri
    Gillman, Jason
    Eron, Joseph
    Santiago, Steven
    Mounzer, Karam
    Sax, Paul
    Mills, Anthony
    Huhn, Gregory
    Moyle, Graeme
    Budday, Matthew
    Elion, Rick
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E220 - E221
  • [22] Utilization of sofosbuvir/velpatasvir in genotype 2-6 HCV: real-world experience from the TRIO network
    Curry, M.
    Bacon, B.
    Dieterich, D.
    Flamm, S.
    Kowdley, K.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Afdhal, N.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S58 - S58
  • [23] Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease
    Rockstroh, Juergen K.
    Ingiliz, Patrick
    Petersen, Joerg
    Peck-Radosavljevic, Markus
    Welzel, Tania M.
    Van der Valk, Marc
    Zhao, Yue
    Jimenez-Exposito, Maria Jesus
    Zeuzem, Stefan
    [J]. ANTIVIRAL THERAPY, 2017, 22 (03) : 225 - 236
  • [24] Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
    Tamai, Hideyuki
    Shingaki, Naoki
    Ida, Yoshiyuki
    Shimizu, Ryo
    Maeshima, Shuya
    Okamura, Junpei
    Kawashima, Akira
    Nakao, Taisei
    Hara, Takeshi
    Matsutani, Hiroyoshi
    Nishikawa, Izumi
    Higashi, Katsuhiko
    [J]. JGH OPEN, 2018, 2 (06): : 300 - 306
  • [25] Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population
    Dieterich, Douglas
    Bacon, Bruce R.
    Flamm, Steven L.
    Kowdley, Kris V.
    Milligan, Scott
    Tsai, Naoky
    Younossi, Zobair
    Lawitz, Eric
    [J]. HEPATOLOGY, 2014, 60 : 220A - 220A
  • [26] Sofosbuvir Plus Ribavirin before Transplantation Prevented HCV Infection Post-Transplant in Patients with HCV Cirrhosis and HCC: Results of an Open-Label Trial
    Curry, Michael P.
    Terrault, Norah
    O'Leary, Jacqueline
    Forns, Xavier
    Brown, Robert, Jr.
    Chung, Raymond T.
    Gane, Edward
    Fenkel, Jonathan M.
    Gordon, Fredric
    Kuo, Alexander
    Schiano, Thomas
    Schiff, Eugene
    Befeler, Alex
    McHutchison, John G.
    Symonds, William T.
    Denning, Jill
    McNair, Lindsay
    Arterburn, Sarah
    Moonka, Dilip
    Everson, Gregory
    Afdhal, Nezam
    [J]. LIVER TRANSPLANTATION, 2014, 20 : S150 - S150
  • [27] EFFICACY EVALUATION OF 24 WEEK SOF + RBV IN A HETEROGENEOUS, REAL-WORLD POPULATION OF GENOTYPE 3 HCV PATIENTS; DATA FROM THE TRIO NETWORK
    Kowdley, K.
    Bacon, B.
    Dieterich, D.
    Lawitz, E.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Flamm, S.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S665 - S666
  • [28] Efficacy Evaluation of 24 Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV Patients; Data From the TRIO Network
    Kowdley, Kris
    Bacon, Bruce
    Dieterich, Douglas T.
    Lawitz, Eric
    Milligan, Scott
    Tsai, Naoky
    Younossi, Zobair M.
    Flamm, Steven L.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1087 - S1087
  • [29] Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several Real-world Datasets (RWD)
    Bourliere, Marc
    Charlton, Michael R.
    Manns, Michael P.
    Prieto, Martin
    Fernandez, Inmaculada
    Londono, Maria-Carlota
    Kwok, Ryan M.
    Smith, Coleman
    Lee, Stacey
    Zhang, Jie
    Arterburn, Sarah
    Osinusi, Anu O.
    Le, Hadley
    Copans, Amanda
    Rossaro, Lorenzo
    Curry, Michael P.
    Flamm, Steven L.
    [J]. HEPATOLOGY, 2016, 64 : 963A - 964A
  • [30] THE IMPACT OF RIBAVIRIN ON REAL WORLD ADHERENCE AND DISCONTINUATION RATES IN HCV PATIENTS TREATED WITH SOFOSBUVIR plus SIMEPREVIR
    Walker, D. R.
    Juday, T. R.
    Manthena, S. R.
    Jing, Y.
    Sood, V.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S664 - S664
12345